Benefits
More Bifidobacteria in the Gut
A 2023 meta-analysis of 50 randomized trials (about 2,500 people) found chicory inulin-type fructans at 3 to 20 g/day increased Bifidobacterium in stool, though not significantly in people with gastrointestinal disorders. This is a change in gut bacteria, not by itself a health outcome, and two of the review's seven authors worked for BENEO, a chicory inulin maker.
Blood Sugar: Little Effect in Most People
A 2024 meta-analysis of 55 randomized trials found little to no effect on fasting glucose or HbA1c. Small reductions appeared only in subgroups of people with diabetes, and a 6-week trial of 16 g/day in type 2 diabetes found no change in glucose, insulin or GLP-1. Inulin is not a way to manage blood sugar.
Small Weight Loss in Trials (Low Certainty)
Pooled trials found about 1 kg (roughly 2 lb) more weight loss than placebo over several weeks to months (Talukdar 2024, 36 trials, low certainty). Trials that measured appetite and calorie intake mostly found no change, so the fullness explanation is not established.
Higher Calcium Absorption in Small Trials
In a 1-year randomized trial in pubertal adolescents, 8 g/day of an inulin plus oligofructose mix raised calcium absorption (by 8.5 percentage points at 8 weeks and 5.9 at 1 year) and increased whole-body bone mineral gain. In adults the evidence is smaller: a 6-week crossover trial of the same kind of mix in 15 postmenopausal women found higher calcium and magnesium absorption than placebo, but only about two-thirds of the women responded. Neither trial measured fractures.
More Frequent Bowel Movements at 12 g/Day
The EU has authorised the claim that chicory inulin contributes to normal bowel function by increasing stool frequency, for 12 g/day of native chicory inulin. In a crossover trial in 44 adults with constipation, 12 g/day gave a median of 4 bowel movements a week versus 3 on placebo. The effect is modest, and products supplying 2 to 5 g/day are below the dose studied.
C-Reactive Protein: Small, Uncertain Change
A 2020 meta-analysis of prebiotic trials in overweight and obese adults found a small drop in C-reactive protein, a blood marker of inflammation, with inulin-type fructans. It is a lab marker from small trials, not a measured reduction in any illness.
Small LDL Cholesterol Reduction (Very Low Certainty)
A 2024 meta-analysis of randomized trials found inulin-type fructans lowered LDL ("bad") cholesterol by about 0.14 mmol/L (about 5 mg/dL) and triglycerides by 0.06 mmol/L, rated very low to low certainty. These are blood markers; the trials did not measure heart attacks or other heart outcomes.
Mechanism of action
Prebiotic Effect
Inulin is a non-digestible fructan that reaches the colon intact, where it is fermented by beneficial gut bacteria (e.g., Bifidobacteria and Lactobacilli). This fermentation produces short-chain fatty acids (SCFAs) like butyrate, acetate, and propionate, which nourish colon cells, enhance gut barrier function, and reduce harmful bacteria.
Improved Gut Motility
Fermentation of inulin increases microbial biomass and SCFA production, which stimulates peristalsis and softens stools, promoting regular bowel movements and relieving constipation.
Blood Sugar (No Consistent Effect)
Inulin is not digested in the small intestine, so it adds almost no glucose itself. Unlike viscous fibers such as psyllium or beta-glucan it forms little gel, and human trials have not shown a consistent effect on blood sugar.
Appetite Hormones (Inconsistent in People)
In rodents, fermentation of these fibers raises the gut hormones GLP-1 and PYY. In people the results conflict. A 2-week trial in 10 adults found higher GLP-1 and PYY after a meal, and a single 24 g dose briefly raised GLP-1 in one small study. But a 6-week trial of 16 g/day in 29 adults with type 2 diabetes found no improvement in GLP-1, PYY or appetite, a 12-week trial of 21 g/day oligofructose found no change in GLP-1, and another acute 24 g dose did not raise GLP-1 or PYY.
Mineral Absorption
Inulin fermentation lowers colon pH, increasing the solubility of calcium and magnesium. Higher calcium absorption was measured in a 1-year trial in adolescents (with greater bone mineral gain) and, for calcium and magnesium, in a 6-week trial in 15 postmenopausal women.
Lipid Metabolism
SCFAs, particularly propionate, may inhibit hepatic cholesterol synthesis and reduce circulating LDL cholesterol and triglycerides, though this mechanism is unproven in people. In pooled human trials the LDL change is small (about 0.14 mmol/L), and effects on inflammation are limited to small changes in a blood marker.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial (Micka et al., Int J Food Sci Nutr 2017; NCT02548247): 4 weeks of 3 x 4 g/day Orafti Inulin versus maltodextrin, with a 2-week washout. Two authors were employed by BENEO, the maker of the inulin tested.
44 otherwise healthy adults with constipation.
Median stool frequency was 4.0 bowel movements a week on inulin versus 3.0 on placebo (p = 0.038), with softer stools and a trend toward higher satisfaction (p = 0.059). The effect is modest: about one extra bowel movement a week.
Randomized, double-blind, placebo-controlled trial (Nishimura et al., J Tradit Complement Med 2015): 300 mL/day of a roasted chicory root extract drink containing 0.25 g inulin per 100 mL, for 4 weeks. This is a whole-root extract, not an inulin supplement.
47 healthy Japanese adults (39 women, 8 men) aged 33 to 70.
No difference from placebo in fasting glucose, insulin or blood lipids, and bowel scores only trended better (p = 0.051). HbA1c fell slightly more than on placebo (0.09 versus 0.03 percentage points, p = 0.018). The drink supplied about 0.75 g of inulin a day, a sixteenth of the 12 g bowel dose, so any effect cannot be credited to inulin.
Systematic review with meta-analyses of randomized trials (Nagy et al., Crit Rev Food Sci Nutr 2023; co-authored by BENEO, a chicory inulin maker), covering Bifidobacterium abundance and bowel function only.
50 randomized trials, 2,525 participants aged 0 to 83 years (Bifidobacterium analysis).
At 3 to 20 g/day, chicory inulin-type fructans increased Bifidobacterium (standardized mean difference 0.83) in healthy people and most patient groups, but not significantly in people with gastrointestinal disorders. Bowel function improved in healthy subjects. Its meta-analyses covered only bifidobacteria and bowel function, not blood lipids or blood sugar.
Randomized, double-blind, placebo-controlled crossover trial (Birkeland et al., Diabet Med 2021; NCT02569684): 16 g/day inulin-type fructans versus maltodextrin for 6 weeks each, 4-week washout, mixed-meal test.
29 adults with type 2 diabetes (Oslo).
No improvement in the meal GLP-1 response (it fell 4.8% after inulin and rose 8.6% after placebo), and no change in fasting or post-meal glucose, insulin or GLP-2. A companion report from the same trial found no benefit for ghrelin, appetite ratings or energy intake, and the PYY response rose on placebo but not on inulin.
Randomized, double-blind, placebo-controlled crossover trial (Puhlmann et al., BMC Gastroenterol 2025; retrospectively registered NCT05447481): 4 weeks of 12 g/day chicory inulin. Three authors were current or former employees of Sensus, an inulin maker.
39 adults with functional constipation (Rome III criteria).
Stool frequency, abdominal symptoms and constipation-related quality of life improved more than on placebo, and butyrate-producing bacteria increased. A carry-over effect biased the crossover, but analysing the first period alone as a parallel trial still favoured inulin.